Astrazeneca Plc (NYSE:AZN) Receives $211.00 Consensus Price Target from Analysts

Astrazeneca Plc (NYSE:AZN) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $206.6667.

AZN has been the topic of a number of research analyst reports. CICC Research began coverage on shares of Astrazeneca in a report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective on the stock. Weiss Ratings downgraded Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Mascoma Wealth Management LLC purchased a new stake in shares of Astrazeneca in the first quarter valued at $26,000. MV Capital Management Inc. purchased a new position in Astrazeneca during the fourth quarter worth about $26,000. Roxbury Financial LLC purchased a new position in Astrazeneca during the second quarter worth about $29,000. Reflection Asset Management acquired a new stake in Astrazeneca in the 4th quarter worth about $31,000. Finally, Resources Management Corp CT ADV acquired a new stake in Astrazeneca in the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

NYSE AZN opened at $162.83 on Friday. The stock has a market capitalization of $252.53 billion, a price-to-earnings ratio of 24.34, a PEG ratio of 1.41 and a beta of 0.26. The business’s 50 day moving average is $171.23 and its two-hundred day moving average is $184.73. Astrazeneca has a 12-month low of $145.79 and a 12-month high of $212.71. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. During the same period in the previous year, the business earned $2.17 earnings per share. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Research analysts expect that Astrazeneca will post 10.19 EPS for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.